A Phase 2, Multicenter, Randomized, Open-label, Parallel-group Study of a Lenalidomide (Revlimid) Regimen or a Sequential Azacitidine (Vidaza) Plus Lenalidomide (Revlimid) Regimen Versus Conventional Care Regimens for Therapy of Older Subjects With Newly Diagnosed Acute Myeloid Leukemia.

Trial Profile

A Phase 2, Multicenter, Randomized, Open-label, Parallel-group Study of a Lenalidomide (Revlimid) Regimen or a Sequential Azacitidine (Vidaza) Plus Lenalidomide (Revlimid) Regimen Versus Conventional Care Regimens for Therapy of Older Subjects With Newly Diagnosed Acute Myeloid Leukemia.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Mar 2017

At a glance

  • Drugs Azacitidine (Primary) ; Lenalidomide (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 02 Feb 2017 Planned End Date changed from 1 Apr 2018 to 1 May 2018.
    • 25 May 2016 Time frame of primary endpoint changed from up to 12 months to up to 24 months.
    • 25 May 2016 Planned End Date changed from 1 Jun 2018 to 1 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top